Table 2.
Study | Follow-up (months) | Patients at follow-up | Death (n) | MI (n) | TLR (n) | ||||
---|---|---|---|---|---|---|---|---|---|
DCB | Control | DCB | Control | DCB | Control | DCB | Control | ||
Habara et al. [19] | 6 | 25 | 25 | 0 | 0 | 0 | 0 | 1 | 10 |
PACCOCATH ISR I AND II [18] | 24 | 54 | 54 | 2 | 3 | 1 | 5 | 3 | 20 |
PEPCAD II ISR [20] | 12 | 66 | 65 | 2 | 3 | 0 | 1 | 4 | 10 |
PEPCAD-DES [23] | 12 | 72 | 38 | 1 | 5 | 0 | 1 | 11 | 14 |
Overall | 217 | 182 | 5 | 11 | 1 | 7 | 19 | 54 |